|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C14orf166 |
Gene summary for C14ORF166 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C14orf166 | Gene ID | 51637 |
| Gene name | RNA transcription, translation and transport factor | |
| Gene Alias | C14orf166 | |
| Cytomap | 14q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000394 | UniProtAcc | Q549M8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51637 | C14orf166 | GSM4909281 | Human | Breast | IDC | 2.44e-15 | -2.90e-01 | 0.21 |
| 51637 | C14orf166 | GSM4909282 | Human | Breast | IDC | 2.44e-15 | -2.90e-01 | -0.0288 |
| 51637 | C14orf166 | GSM4909285 | Human | Breast | IDC | 2.44e-15 | -2.90e-01 | 0.21 |
| 51637 | C14orf166 | GSM4909286 | Human | Breast | IDC | 5.48e-15 | -2.90e-01 | 0.1081 |
| 51637 | C14orf166 | GSM4909287 | Human | Breast | IDC | 4.02e-18 | -2.90e-01 | 0.2057 |
| 51637 | C14orf166 | GSM4909288 | Human | Breast | IDC | 8.02e-04 | -2.90e-01 | 0.0988 |
| 51637 | C14orf166 | GSM4909289 | Human | Breast | IDC | 1.80e-02 | -2.90e-01 | 0.1064 |
| 51637 | C14orf166 | GSM4909290 | Human | Breast | IDC | 7.88e-13 | -2.90e-01 | 0.2096 |
| 51637 | C14orf166 | GSM4909291 | Human | Breast | IDC | 2.70e-10 | -2.90e-01 | 0.1753 |
| 51637 | C14orf166 | GSM4909293 | Human | Breast | IDC | 1.08e-15 | -2.90e-01 | 0.1581 |
| 51637 | C14orf166 | GSM4909294 | Human | Breast | IDC | 2.12e-16 | -2.90e-01 | 0.2022 |
| 51637 | C14orf166 | GSM4909295 | Human | Breast | IDC | 5.68e-08 | -2.90e-01 | 0.0898 |
| 51637 | C14orf166 | GSM4909296 | Human | Breast | IDC | 1.08e-15 | -2.90e-01 | 0.1524 |
| 51637 | C14orf166 | GSM4909297 | Human | Breast | IDC | 1.51e-18 | -2.90e-01 | 0.1517 |
| 51637 | C14orf166 | GSM4909298 | Human | Breast | IDC | 4.12e-17 | -2.90e-01 | 0.1551 |
| 51637 | C14orf166 | GSM4909299 | Human | Breast | IDC | 4.80e-16 | -2.90e-01 | 0.035 |
| 51637 | C14orf166 | GSM4909300 | Human | Breast | IDC | 5.69e-07 | -2.90e-01 | 0.0334 |
| 51637 | C14orf166 | GSM4909301 | Human | Breast | IDC | 4.12e-17 | -2.90e-01 | 0.1577 |
| 51637 | C14orf166 | GSM4909302 | Human | Breast | IDC | 7.44e-18 | -2.90e-01 | 0.1545 |
| 51637 | C14orf166 | GSM4909303 | Human | Breast | IDC | 1.98e-04 | -2.90e-01 | 0.0438 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C14orf166 | insertion | Frame_Shift_Ins | novel | c.623_624insTGGG | p.Ile209GlyfsTer25 | p.I209Gfs*25 | Q9Y224 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| C14orf166 | SNV | Missense_Mutation | c.562N>A | p.Leu188Ile | p.L188I | Q9Y224 | protein_coding | tolerated(0.13) | benign(0.207) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| C14orf166 | SNV | Missense_Mutation | c.177C>A | p.Phe59Leu | p.F59L | Q9Y224 | protein_coding | tolerated(0.64) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| C14orf166 | SNV | Missense_Mutation | rs748105780 | c.41N>T | p.Pro14Leu | p.P14L | Q9Y224 | protein_coding | tolerated(0.46) | probably_damaging(0.951) | TCGA-D5-6932-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| C14orf166 | SNV | Missense_Mutation | c.562C>A | p.Leu188Ile | p.L188I | Q9Y224 | protein_coding | tolerated(0.13) | benign(0.207) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C14orf166 | SNV | Missense_Mutation | c.377A>C | p.Asn126Thr | p.N126T | Q9Y224 | protein_coding | deleterious(0.02) | benign(0.01) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C14orf166 | SNV | Missense_Mutation | novel | c.82N>C | p.Phe28Leu | p.F28L | Q9Y224 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C14orf166 | SNV | Missense_Mutation | novel | c.560N>G | p.Ile187Ser | p.I187S | Q9Y224 | protein_coding | tolerated(0.74) | benign(0.062) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C14orf166 | SNV | Missense_Mutation | c.562N>T | p.Leu188Phe | p.L188F | Q9Y224 | protein_coding | deleterious(0.02) | possibly_damaging(0.65) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C14orf166 | SNV | Missense_Mutation | c.215N>G | p.Lys72Arg | p.K72R | Q9Y224 | protein_coding | tolerated(0.28) | benign(0.174) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |